Ocular Surface Regeneration by Limbal Stem Cells Therapies: State of the Art, Challenges, and Perspectives
3D bioprinting of corneal models: A reviewof the current state and future outlook
15 September 2023
Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science
26 September 2023

Stem Cells Transl Med. 2023 Sep 16:szad058. doi: 10.1093/stcltm/szad058. Epub ahead of print. PMID: 37715946.

Ocular Surface Regeneration by Limbal Stem Cells Therapies: State of the Art, Challenges, and Perspectives

Authors: Clémence Bonnet 1 2Sheyla González 1Sophie X Deng 1 3


  • 1Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA, USA.
  • 2Ophthalmology Department, Cochin Hospital and Université Paris Cité, Paris, France.
  • 3Molecular Biology Institute, University of California, Los Angeles, CA, USA.


Limbal stem cells (LSCs) are adult stem cells located at the limbus ensuring the continuous renewal of the corneal epithelium, critical to maintain an optimal visual function. Damages to the LSCs or their niche microenvironment lead to limbal stem cell deficiency (LSCD), a potentially blinding disease. Transplantation of LSCs as a treatment for severe to total LSCD has gained popularity since 1980s, owing to the clinical success of the first direct limbal autograft transplantation. Recent advances in the understanding of the LSCs’ molecular identity and regulation have enabled preclinical and clinical advancements of promising LSCs therapies. However, lack of standardization of the diagnostic methods, staging of the disease severity, manufacturing process, and clinical outcome measures have hindered the advancement of the therapy. To move these therapies to the clinic, optimization and standardization of the diagnostic strategy, cell product manufacturing, and assessment of clinical efficacy with potency assays are key points to the development of customized therapies. Recent findings suggest that residual LSCs exist in eyes presenting with clinical signs of total LSCD, which opens new therapeutic strategies for eyes with partial LSCD. Prospective, randomized, multicentric controlled clinical trials are necessary to determine the efficacy of different LSCs therapies for different stages of LSCD using a set of standardized outcome measures.

Download: https://academic.oup.com/stcltm/advance-article/doi/10.1093/stcltm/szad058/7275634